Cited by 1,860HER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, Charles L., Cobleigh, Melody A., Tripathy, Debu, Gutheil, John C., Harris, Lyndsay N., Fehrenbacher, Louis, Slamon, Dennis J., Murphy, Maureen, Novotny, William F., Burchmore, Michael, Shak, Steven, Stewart, Stanford J., Press, Michael·2002·Journal of Clinical Oncology

DOI 10.1200/jco.2002.20.3.719

Open this paper in CoChat — free account

Abstract

PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.20.3.719

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Self-citation
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Self-citation
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P. M., Presta, L. G., Gorman, C., Ridgway, J. B., Henner, D. J., Wong, W., Rowland, A. M., Kotts, C. E., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,926
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. E. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 974
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 250
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I. O., Locker, A. P., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237

Show all 9 references

Sorted by citations

Items 701–800 of 1,009

Dual in vivo Photoacoustic and Fluorescence Imaging of HER2 Expression in Breast Tumors for Diagnosis, Margin Assessment, and Surgical Guidance
Maeda, A., Bu, J., Chen, J., Zheng, G., & DaCosta, R. S. (2015) · Molecular Imaging · doi:10.2310/7290.2014.00043 · Cited by 42
Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany
Rüschoff, J., Lebeau, A., Kreipe, H. H., Sinn, H., Gerharz, C. D., Koch, W., Morris, S., Ammann, J. U., & Untch, M. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.164 · Cited by 42
Targeting protein quality control pathways in breast cancer
Sannino, S., & Brodsky, J. L. (2017) · BMC Biology · doi:10.1186/s12915-017-0449-4 · Cited by 43
Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics
CHRISTOPOULOS, P. F., Corthay, A., & Koutsilieris, M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.010 · Cited by 46
Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2
Tobin, S. J., Wakefield, D. L., Jones, V., Liu, X., Schmolze, D. B., & Jovanović‐Talisman, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-33225-0 · Cited by 43
Efficacy and Safety of Trastuzumab as a Single Agent in Heavily Pretreated Patients with Her-2/NEU-Overexpressing Metastatic Breast Cancer
Sawaki, M., Ito, Y., Tada, K., Mizunuma, N., Takahashi, S., Horikoshi, N., Kasumi, F., Akiyama, F., Sakamoto, G., Imai, T., et al. (2004) · Tumori Journal · doi:10.1177/030089160409000110 · Cited by 42
Generation of an enriched pool of DNA aptamers for an HER2‐overexpressing cell line selected by Cell SELEX
Dastjerdi, K., Tabar, G. H., Dehghani, H., & Haghparast, A. (2011) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.36 · Cited by 42
Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study
Kluger, H. M., DiVito, K. A., Berger, A. J., Halaban, R., Ariyan, S., Camp, R. L., & Rimm, D. L. (2004) · Melanoma Research · doi:10.1097/01.cmr.0000130874.33504.2f · Cited by 42
Ziyuglycoside II Inhibits the Growth of Human Breast Carcinoma MDA-MB-435 Cells via Cell Cycle Arrest and Induction of Apoptosis through the Mitochondria Dependent Pathway
Zhu, X., Wang, K., Zhang, K., Huang, B., Zhang, J., Zhang, Y., Zhu, L., Zhou, B., & Zhou, F. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918041 · Cited by 42
Lipid-Rich Carcinoma of the Breast. A Clinicopathological Study of 49 Cases
Shi, P., Wang, M., Zhang, Q., & Sun, J. (2008) · Tumori Journal · doi:10.1177/030089160809400309 · Cited by 42
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells
Ozbay, T., Durden, D. L., Liu, T., O'Regan, R. M., & Nahta, R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1075-9 · Cited by 41
Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5
Ward, T. M., Iorns, E. J., Liu, X., Hoe, N., Kim, P., Singh, S., Dean, S., Jegg, A.-M., Gallas, M., Rodriguez, C., et al. (2012) · Oncogene · doi:10.1038/onc.2012.256 · Cited by 42
Epigenetic Mechanisms in Commonly Occurring Cancers
Blair, L. P., & Yan, Q. (2012) · DNA and Cell Biology · doi:10.1089/dna.2012.1654 · Cited by 41
Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade
Singh, R., Kim, W. J., Kim, P.-H., & Hong, H. J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.111 · Cited by 41
Targeted Nanodiamonds as Phenotype-Specific Photoacoustic Contrast Agents for Breast Cancer
Zhang, T., Cui, H., Fang, C., Cheng, K., Yang, X., Chang, H., & Forrest, M. L. (2015) · Nanomedicine · doi:10.2217/nnm.14.141 · Cited by 41
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention
Nocera, N. F., Lee, M. C., Cruz, L. M. D. L., Rosemblit, C., & Czerniecki, B. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00356 · Cited by 41
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
Press, M. F., Ellis, C. E., Gagnon, R., Grob, T. J., Buyse, M. E., Villalobos, I. E., Liang, Z., Wu, S., Bang, Y., Qin, S.-K., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0887 · Cited by 41
Self-citation
Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas
Sett, A., Borthakur, B. B., & Bora, U. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1629-y · Cited by 41
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Agersborg, S. S., Mixon, C., Nguyen, T. T. N., Aithal, S., Sudarsanam, S., Blocker, F., Weiss, L. M., Gasparini, R., Jiang, S., Chen, W., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4755-5 · Cited by 41
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
Cheal, S. M., Xu, H., Guo, H.-F., Patel, M., Punzalan, B. J., Fung, E. K., Lee, S., Bell, M. M., Singh, M., Jungbluth, A. A., et al. (2018) · Theranostics · doi:10.7150/thno.26585 · Cited by 41
Evolving treatment strategies of brain metastases from breast cancer: current status and future direction
Kim, J. S., & Kim, I. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936117 · Cited by 41
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
Witzel, I., Müller, V., Abenhardt, W., Kaufmann, M., Schoenegg, W., Schneeweis, A., & Jänicke, F. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-806 · Cited by 41
Immunocytochemical evaluation of HER‐2/neu on fine‐needle aspirates from primary breast carcinomas
Nizzoli, R., Bozzetti, C., Crafa, P., Naldi, N., Guazzi, A., Blasio, B. D., Camisa, R., & Cascinu, S. (2003) · Diagnostic Cytopathology · doi:10.1002/dc.10257 · Cited by 41
Amplification of HER2 is a marker for global genomic instability
Ellsworth, R. E., Ellsworth, D. L., Patney, H. L., Deyarmin, B., Love, B., Hooke, J. A., & Shriver, C. D. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-297 · Cited by 41
Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer
Zhang, C., Han, Y. K., Huang, H., Min, L., Qu, L., & Shou, C. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2352 · Cited by 40
Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
Brady, S. W., Zhang, J., Seok, D., Wang, H., & Yu, D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0518 · Cited by 40
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options
Jiang, H., & Rugo, H. S. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015599389 · Cited by 40
Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids
Rodriguez, C. E., Reidel, S. I., Joffé, E. B. D. K., Jasnis, M. A., & Fiszman, G. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137920 · Cited by 40
GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma
Bivin, W. W., Yergiyev, O., Bunker, M. L., Silverman, J. F., & Krishnamurti, U. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000349 · Cited by 40
Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections
Rost, S., Giltnane, J. M., Bordeaux, J., Hitzman, C., Koeppen, H., & Liu, S. D. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.50 · Cited by 40
Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer
Zhang, C., Zhang, F., Han, M., Wang, X., Du, J., Zhang, H., & Li, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-79125-0 · Cited by 42
Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH
Desmedt, C., Sperinde, J., Piette, F., Huang, W., Jin, X., Tan, Y., Durbecq, V., Larsimont, D., Giuliani, R., Chappey, C., et al. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31818ebc69 · Cited by 40
Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated
Leyland-Jones, B. R., Colomer, R., Trudeau, M., Wardley, A. M., Latreille, J., Cameron, D., Cubedo, R., Al-Sakaff, N. J. A., Feyereislova, A., Catalani, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1910 · Cited by 40
The Molecular Analysis of Breast Cancer Utilizing Targeted Nanoparticle Based Ultrasound Contrast Agents
Sakamoto, J. H., Smith, B. R., Xie, B., Rokhlin, S. I., Lee, S. C., & Mauro Ferrari, B. (2005) · Technology in Cancer Research & Treatment · doi:10.1177/153303460500400606 · Cited by 40
Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Johnson, B. E., & Janne, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0629 · Cited by 40
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
Holler, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s340741 · Cited by 47
Targeted Inhibition of Kinases in Cancer Therapy
Baker, S. J., & Reddy, E. P. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20220 · Cited by 39
High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines
Vergara‐Lluri, M., Moatamed, N. A., Hong, E., & Apple, S. K. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.93 · Cited by 39
Localized Visualization and Autonomous Detection of Cell Surface Receptor Clusters Using DNA Proximity Circuit
Ang, Y. S., Li, J. J., Chua, P., Ng, C.-T., Bay, B., & Yung, L. L. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00722 · Cited by 39
Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1
Shah, D., Wyatt, D. L., Baker, A. T., Simms, P. E., Peiffer, D. S., Fernandez, M., Rakha, E. A., Green, A. R., Filipovic, A., Miele, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1952 · Cited by 39
The emerging role of antibody-drug conjugates in urothelial carcinoma
Lattanzi, M. W., & Rosenberg, J. E. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1782201 · Cited by 42
Cancer Stem Cell-Targeted Therapeutic Approaches for Overcoming Trastuzumab Resistance in HER2-Positive Breast Cancer
Qiu, Y., Yang, L., Liu, H., & Luo, X. (2021) · Stem Cells · doi:10.1002/stem.3381 · Cited by 41
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
Gelardi, T., Damiano, V., Rosa, R., Bianco, R., Cozzolino, R., Tortora, G., Laccetti, P., D’Alessio, G., & Lorenzo, C. D. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605499 · Cited by 39
EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer
Dubey, S., Stephenson, P. A., Levy, D. E., Miller, J., Keller, S. M., Schiller, J. H., Johnson, D. H., & Kolesar, J. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31603-8 · Cited by 39
Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo
Guan, H., Jia, S.-F., Zhou, Z., Stewart, J., & Kleinerman, E. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0777 · Cited by 39
Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer, T., Wiedswang, G., Boudjema, G., Christensen, H., & Kåresen, R. (2003) · Apmis · doi:10.1034/j.1600-0463.2003.t01-1-1110210.x · Cited by 39
Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand
Kulhari, H., Pooja, D., Rompicharla, S. V. K., Sistla, R., & Adams, D. J. (2015) · Medicinal Research Reviews · doi:10.1002/med.21345 · Cited by 38
Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts
Walsh, A. J., Cook, R. S., Lee, J. H., Arteaga, C. L., & Skala, M. C. (2015) · Journal of Biomedical Optics · doi:10.1117/1.jbo.20.2.026004 · Cited by 38
Predicting synergistic effects between compounds through their structural similarity and effects on transcriptomes
Liu, Y., & Zhao, H. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw509 · Cited by 38
Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels
Zhang, X., Zhao, Y., Wang, C., Ju, H., Liu, W., Zhang, X., Miao, S., Wang, L., Sun, Q., & Song, W. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0267-5 · Cited by 38
HER2-low breast cancers: Current insights and future directions
Zhang, H., Karakaş, C., Tyburski, H., Turner, B. M., Peng, Y. S., Wang, X., Katerji, H., Schiffhauer, L. M., & Hicks, D. G. (2022) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2022.07.003 · Cited by 38
Breast cancer (metastatic).
Stebbing, J., Crane, J., & Gaya, A. (2002) · Europe PMC (PubMed Central) · Cited by 38
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
Esteva, F. J., Wang, J., Lin, F., Mejia, J. A., Yan, K., Altundağ, K., Valero, V., Buzdar, A. U., Hortobágyi, G. N., Symmans, W. F., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1836 · Cited by 38
First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors
Münster, P. N., Britten, C. D., Mita, M. M., Gelmon, K. A., Minton, S. E., Moulder, S. L., Slamon, D. J., Guo, F., Letrent, S. P., Denis, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1539 · Cited by 38
Self-citation
Effect of γ-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene
Menéndez, J. A., Vellón, L., Colomer, R., & Lupu, R. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji343 · Cited by 38
HER-2-Positive Breast Cancer
Bartsch, R., Wenzel, C., Zielinski, C. C., & Steger, G. G. (2007) · BioDrugs · doi:10.2165/00063030-200721020-00001 · Cited by 38
Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status
Quan, M.-Y., Huang, Y., Wang, C., Zhang, Q., Chang, C., & Zhou, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1144812 · Cited by 37
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Bittner, B., & Schmidt, J. (2023) · BioDrugs · doi:10.1007/s40259-023-00626-1 · Cited by 37
Predicting survival in women with breast cancer and brain metastasis
Marko, N. F., Xu, Z., Gao, T., Kattan, M. W., & Weil, R. J. (2011) · Cancer · doi:10.1002/cncr.26716 · Cited by 37
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer
Melisko, M., Glantz, M., & Rugo, H. S. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1243 · Cited by 37
Targeting Tumors with Small Molecule Peptides
Cheetham, A. G., Keith, D., Zhang, P., Lin, R., Su, H., & Cui, H. (2016) · Current Cancer Drug Targets · doi:10.2174/1568009616666151130214646 · Cited by 37
Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead‐Assisted Flow Cytometry Detection of Tumor‐Derived Extracellular Vesicles
Li, W., Shao, B., Liu, C., Wang, H., Zheng, W., Kong, W., Liu, X., Xu, G., Wang, C., Li, H., et al. (2018) · Small Methods · doi:10.1002/smtd.201800122 · Cited by 37
Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
Maria, B., Sims, A. H., & Simon, P. L. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0062 · Cited by 37
Development of α‐Gal–Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies
Sianturi, J., Manabe, Y., Li, H., Chiu, L., Chang, T., Tokunaga, K., Kabayama, K., Tanemura, M., Takamatsu, S., Miyoshi, E., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812914 · Cited by 37
TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
Kupryjańczyk, J., Mądry, R., Plisiecka-Hałasa, J., Bar, J. K., Kraszewska, E., Ziółkowska, I., Timorek, A., STELMACHÓW, J., Emerich, J., Jędryka, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602238 · Cited by 37
Hunk is required for HER2/neu-induced mammary tumorigenesis
Yeh, E. S., Yang, T. W., Jung, J. J., Gardner, H. P., Cardiff, R. D., & Chodosh, L. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42928 · Cited by 36
Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)
Fuchs, I. B., Landt, S., Bueler, H., Kuehl, U., Coupland, S. E., Kleine-Tebbe, A., Lichtenegger, W., & Schäller, G. (2003) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000003916.39959.73 · Cited by 37
Her-2/neu expression in locally advanced breast carcinomas: pre- and post-neoadjuvant chemotherapy
(ASCP), B., Quddus, M. R., BS, Sung, C. J., Zhang, C., Pasqueriello, T., Eklund, M. J., & Steinhoff, M. M. (2005) · Breast Cancer · doi:10.2325/jbcs.12.294 · Cited by 37
HER2-positive male breast cancer: an update
Ottini, L., Ottini, L., Capalbo, C., Rizzolo, P., Silvestri, V., Rizzo, & Russo (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s6519 · Cited by 37
Clinical trials of intracellular signal transductions inhibitors for breast cancer — a strategy to overcome endocrine resistance
Johnston, S. R. D. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00992 · Cited by 37
MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance
Paulson, A. K., Linklater, E. S., Berghuis, B. D., App, C. A., Oostendorp, L. D., Paulson, J. E., Pettinga, J., Melnik, M. K., Woude, G. F. V., & Graveel, C. R. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0042 · Cited by 38
Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment
Liu, M., Li, Z., Yang, J., Jiang, Y., Chen, Z., Ali, Z., He, N., & Wang, Z. (2016) · Cell Proliferation · doi:10.1111/cpr.12266 · Cited by 37
A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab
Esteva, F. J., Stebbing, J., Wood-Horrall, R. N., Winkle, P. J., Lee, S., & Lee, S. J. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3510-7 · Cited by 36
Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
Figura, N. B., Long, W., Yu, M. A., Robinson, T. J., Mokhtari, S., Etame, A. B., Tran, N., Díaz, R., Soliman, H. H., Han, H. S., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4684-3 · Cited by 36
Prognostic implications of HER2 heterogeneity in gastric cancer
Motoshima, S., Yonemoto, K., Kamei, H., Morita, M., & Yamaguchi, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24265 · Cited by 36
Therapeutic Options for Metastatic Breast Cancer
Sambi, M., Qorri, B., Harless, W. W., & Szewczuk, M. R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_8 · Cited by 37
Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies
Xiao, H., Jensen, P. E., & Chen, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184360 · Cited by 36
Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity
Syed, A., Filandr, F., Patterson-Fortin, J., Bacolla, A., Ravindranathan, R., Zhou, J., McDonald, D. T., Albuhluli, M. E., Verway-Cohen, A., Newman, J. A., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad727 · Cited by 36
Production and characterization of highly tumor‐specific rat monoclonal antibodies recognizing the extracellular domain of human l ‐type amino‐acid transporter 1
Ohno, Y., Suda, K., Masuko, K., Yagi, H., Hashimoto, Y., & Masuko, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00770.x · Cited by 36
Molecularly Targeted Therapies for Breast Cancer
Hobday, T. J., & Perez, E. A. (2005) · Cancer Control · doi:10.1177/107327480501200202 · Cited by 36
Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Results in Alterations in Preoperative Tumor Marker Status
Piper, G. L., Patel, N. A., Patel, J. A., Malay, M. B., & Julian, T. B. (2004) · The American Surgeon · doi:10.1177/000313480407001215 · Cited by 36
Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells
Lee, H., Park, S., Kim, J. B., Kim, J., & Kim, H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.021 · Cited by 35
Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment
Reddy, S., Shaller, C. C., Doss, M., Shchaveleva, I., Marks, J. D., Yu, J. Q., & Robinson, M. K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1654 · Cited by 35
Autofluorescence imaging captures heterogeneous drug response differences between 2D and 3D breast cancer cultures
Cannon, T. M., Shah, A. T., & Skala, M. C. (2017) · Biomedical Optics Express · doi:10.1364/boe.8.001911 · Cited by 35
Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
Kong, X., Zhang, K., Wang, X., Yang, X. C., Li, Y., Zhai, J., Xing, Z., Qi, Y., Gao, R., Feng, X., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s194137 · Cited by 35
Photoacoustic imaging biomarkers for monitoring biophysical changes during nanobubble-mediated radiation treatment
Hysi, E., Fadhel, M. N., Wang, Y., Sebastian, J. A., Giles, A., Czarnota, G. J., Exner, A. A., & Kolios, M. C. (2020) · Photoacoustics · doi:10.1016/j.pacs.2020.100201 · Cited by 35
Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation
Rivas, M. A., Tkach, M., Béguelin, W., Proietti, C. J., Rosemblit, C., Charreau, E. H., Elizalde, P. V., & Schillaci, R. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0546-3 · Cited by 35
HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor Growth In Vivo
Kawamoto, M., Horibe, T., Kohno, M., & Kawakami, K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0357 · Cited by 35
Predictive Biomarkers for Treatment Selection: Statistical Considerations
Chen, J. J., Lu, T., Chen, Y., & Lin, W. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.84 · Cited by 35
New Drugs in Cancer Therapy, National Tumor Institute, Naples, 17???18 June 2004
Caponigro, F., Basile, M. L., Rosa, V. D., & Normanno, N. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200502000-00014 · Cited by 35
The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations
Lin, A., & Rugo, H. S. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0008-2 · Cited by 35
Expression of HER‐2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in‐situ hybridization and immunohistochemistry
Dagrada, G. P., Negri, T., Tamborini, E., Pierotti, M. A., & Pilotti, S. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.01781.x · Cited by 35
Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu – a new method of epitope definition
Riemer, A. B., Kraml, G., Scheiner, O., Zielinski, C. C., & Jensen‐Jarolim, E. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.11.003 · Cited by 35
The Integration of Molecular Diagnostics With Therapeutics
Ross, J. S., & Ginsburg, G. S. (2003) · American Journal of Clinical Pathology · doi:10.1309/vmll66y5khq35kue · Cited by 35
Targeting the tumour cell surface in advanced prostate cancer
Boixareu, C., Taha, T., Venkadakrishnan, V. B., Bono, J. S. D., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01014-w · Cited by 43
Biological signalling activity measurements using mass spectrometry.
Cutillas, P., & Jorgensen, C. (2011) · Biochemical Journal · doi:10.1042/bj20101974 · Cited by 30
Cancer biomarkers, companion diagnostics and personalized oncology
Ross, J. S. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.29 · Cited by 34
Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases
Cha, M. Y., Lee, K., Kang, S.-J., Jung, Y. H., Song, J. Y., Choi, K. J., Byun, J. Y., Lee, H., Lee, G. S., Park, S. B., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201758g · Cited by 34
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
Bilous, M., Morey, A. L., Armes, J. E., Bell, R. H., Button, P., Cummings, M. C., Fox, S. B., Francis, G. D., Waite, B., McCue, G., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2093-6 · Cited by 34
Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
Zhu, Y., Tian, T., Zou, J., Wang, Q., Li, Z., Li, Y., Liu, X., Dong, B., Li, N., Gao, J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1900-y · Cited by 34

Authors: Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., & Press, M.
Affiliations: University of Southern California (US)
ORCID: Cobleigh, Melody A.
Tripathy, Debu
Harris, Lyndsay N.
Fehrenbacher, Louis
Slamon, Dennis J.
Novotny, William F.
Shak, Steven
Press, Michael
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2002-02-01
Volume: 20
Issue: 3
Pages: 719-726
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2002.20.3.719
OpenAlex: W4239989216
Cited by: 1,860
References: 9
Citations by year: 2026: 12 · 2025: 34 · 2024: 52 · 2023: 75 · 2022: 113 · 2021: 67 · 2020: 72 · 2019: 62 · 2018: 97 · 2017: 95 · 2016: 87 · 2015: 88 · 2014: 71 · 2013: 91 · 2012: 74
FWCI: 32.63
Type: journal article
Language: en
Update notices: new_edition (2023-03-15)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
Funders: National Cancer Institute (CA48780)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: trastuzumab, HER2-positive breast cancer, metastatic breast cancer, first-line therapy, single-agent chemotherapy, HER2 immunohistochemistry, HER2 amplification, objective response rate, adverse cardiac events, dose-response relationship, treatment safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks